Insight Molecular Diagnostics (IMDX) Capital Expenditures Growth (1y) (2016 - 2026)
Insight Molecular Diagnostics (IMDX) Capital Expenditures Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 53.06% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 8.47% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 144.93% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | -33.33% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 31.13% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | -27.73% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 33.33% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 16.40% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 68.93% |
| 10 | Insight Molecular Diagnostics | 158.03 Mn | 139.50 Mn | 157,000.00 | 123.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 123.21% |
| Mar 31, 2026 | 99.67% |
| Dec 31, 2025 | 591.12% |
| Sep 30, 2025 | 1,106.90% |
| Jun 30, 2025 | 82.72% |
| Mar 31, 2025 | 1,179.17% |
| Dec 31, 2024 | -18.94% |
| Sep 30, 2024 | 115.43% |
| Dec 31, 2023 | -67.08% |
| Sep 30, 2023 | -165.66% |
| Dec 31, 2022 | 100.00% |
| Sep 30, 2022 | 118.02% |
| Jun 30, 2022 | 83.28% |
| Mar 31, 2022 | 85.39% |
| Dec 31, 2021 | 141.57% |
| Sep 30, 2021 | -25.10% |
| Jun 30, 2021 | 24.24% |
| Mar 31, 2021 | 1,813.64% |
| Dec 31, 2020 | -81.56% |
| Jun 30, 2020 | 4,363.64% |